During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the AML Hub spoke to Eytan Stein, Memorial Sloan Kettering Cancer Center, New York, US. We asked, Does enasidenib and azacitidine sequential therapy improve outcomes in older patients with IDH2 AML?